Instytut Immunologii I Terapii Doswiadczalnej Pan

Uniwersytet Jagiellonski

Wroclawskie Centrum Badan Eit+ Sp. Z O.o.

Instytut Immunologii I Terapii

Instytut Immunologii I Terapii Doswiadczainej Im. Ludwika Hirszfelds Pan

Uniwersytet Medyczny Im. Piastow Slaskich We Wroclawiu

Wroclawskie Centrum Baden Eit+sp Z O.o.

Instytut Immunologii I Terapii Doswiadczalnej Polskiej Akademii Nauk

Instytut Immunologii I Terapii Doswiadczalnej Lm. Ludwika Hirszfelda Polskiej Akademii Nauk

Siec Badawcza Lukasiewicz - Port Polski Osrodek Rozwoju Technologii

Instytut Immunologii I Terapii Doswiadczalnej Im. Ludwika Hirszfelda Pan

Andrzej Gamian

Tomasz Lipiński

Monika Brzychczy-Wloch

Ewa Brzozowska

Agnieszka Korzeniowska-Kowal

Sabina Gorska

Ewa Zuziak

Andrzej Gorski

Andrzej Górski

Magdalena Staniszewska

Anna Dobrut

Andrzej Myc

Agnieszka Razim

Jacek Rybka

Arkadiusz Bartys

Regina Danielewicz

Katarzyna Dzierzba

Jadwiga Pietkiewicz

Edmund Ziomek

Danuta Witkowska

Anna Ewelina Jarząb

Piotr Ziolkowski

Agata Kochman

Piotr Heczko

Sabina Górska

Agnieszka Szydelko

Grzegorz Mazur

Tomasz Lipinski

Kazimiera Wilk

Urszula Cibor

Piotr ZIÓLKOWSKI

Renata Frackowiak

Jerzy Wisniewski

Sebastian Makuch

Monika Krawczyk

Siddarth Agrawal

Gabriela Pastuch-Gawolek

Marta Wozniak

The present invention relates to a veterinary vaccine containing nanoadjuvants in the form of emulsion andantigens, as well as the use of the vaccine in the preventions and treatment of ainfection, especially in birds and mammals. The object of the invention is also the use of this vaccine to produce-specific antibodies.

Vaccine for the prevention and treatment of C. difficile infections and the use thereof

The method according to the invention enables the confirmation of infections/carriage caused bybacterial species. The method employs a specific reaction of selected epitopes that are part of immunoreactive proteins of clinical isolates ofwith antibodies present in the serum.

Diagnostic test

The method of the invention allows confirmation of infections caused bybacterial species. The method employs a specific reaction of immunoreactive proteins obtained from clinical isolates ofwith antibodies present in the serum of patients.

[object Object]

We disclose the use of bacterial antigens and obtained antibodies. The resulting antibodies can be used in the diagnosis of tumors by immunohistochemistry and in the binding of drugs to antibodies for use in cancer therapy.

Antibody possessing an affinity for epithelial secretory and nervous tissue, as well as tumour tissue derived from these tissues as well as the use thereof

An isolated protein containing a common epitope recognized by umbilical blood antibodies specific against enterobacteria, occurring in an extract of bacterial outer membrane proteins, and fragments thereof containing said common epitope, which can be used in medicine and pharmaceutics, particularly in the production of vaccines and diagnostic tests as well as affinity materials.

Epitope and its use

A method of preparation of purified bacteriophage with increased antibacterial activity, in which from bacterial lysate of phages is obtained, advantageously in the presence of lysozyme, chelating factor and detergent, in a continuous manner with ultrafiltration on membranes, the phage containing high molecular mass preparation, devoid of bacterial cell wall and other contaminants, free of toxins and endotoxins, active in tests of bacterial lysis, which is characterized by chromatography HPLC, In SDS-PAGE electrophoresis, immunoblotting, biological tests of bacterial lysis, and is dedicated for phage therapy of bacterial infections and tumors and for production of phage deriving pharmaceutical preparations.

Purified bacteriophage, its preparation and application

The subject the present invention is a method of producing a pharmacologically stable form of purified and lyophilised bacteriophage preparations of increased stability and antibacterial activity, characterized in that phages produced from a bacterial lysate, for example by ultrafiltration on ultrafiltration membranes, containing a high molecular weight preparation of purified phages is stabilised most preferably with a probiotic extract in the presence or absence of neutral salts and/or organic solvents, lyophilised, characterised via HPLC chromatography, by SDS-PAGE, and bacterial lysis biological assays, and then stored under a vacuum, where the active lyophilisate is destined for phage therapy of infections and tumors.

Method of producing a pharmacologically stable form of lyophilised, active preparations of purified bacteriophages

The subject of the present invention is a pure monomeric bovine serum albumin, a method of producing it characterised by the use column chromatography in resin and a method of identifying it using dynamic light scattering.

Pure albumin and its method of preparation and detection

The subject the present invention is a method of producing affinity beds with bacterial lipopolysaccharide molecules bound to them in a non-covalent and stable fashion. The bed produced according to the present invention may be used in affinity chromatography for the purification of antibodies against lipopolysaccharides. It is particularly useful in the purification of antibodies against the labile epitopes of lipopolysaccharides, which degrade in heretofore used methods of covalent bonding of the lipopolysaccharide molecules to the solid phase.

Method of binding bacterial lipopolysaccharides to a solid phase

Growing community of inventors

Wroclaw, Poland

Andrzej Gamian